Enhance Neurodegenerative Detection and Monitoring with BD-pTau 217 and α-Syn

The ability to reliably detect blood-based biomarkers such as brain-derived pTau 217 (BD-pTau 217) and α-synuclein species across healthy and disease populations has remained a significant challenge in neurodegenerative disease research. Recent advances in ultra-sensitive immunoassay technology are now addressing these limitations, enabling consistent quantification of these low-abundance biomarkers and expanding their utility across early detection, longitudinal monitoring and translational research applications in neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.

This webinar will explore how specific platforms can enable robust measurement of BD-pTau 217, total α-synuclein (α-syn) and phosphorylated α-synuclein (pS129-α-syn) in blood. By enabling reliable detectability across cohorts, including healthy individuals and across disease stages, specific platforms provide a foundation for more consistent and interpretable biomarker data in clinical disease research.

The featured speaker will highlight the value of BD-pTau 217 as a highly specific biomarker for Alzheimer’s pathology, alongside total α-syn and pS129-α-syn as key markers for Parkinson’s disease and related synucleinopathies. Importantly, the ability to measure both total and phosphorylated α-synuclein concurrently on the same platform enables new analytical approaches, including ratio-based analyses, to support deeper insights into disease biology, patient stratification and disease progression.

The speaker will also lead a data-driven discussion on key analytical considerations for ultra-low-abundance biomarker detection, including achieving high sensitivity while maintaining assay specificity, reproducibility and longitudinal precision. These advances are enabling researchers to track subtle biological changes with greater confidence and expand biomarker applications across the full clinical research continuum.

Register for this webinar to learn how BD-pTau 217 and α-synuclein species support early detection, longitudinal monitoring and biomarker research in neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.

Speaker

Dr. Tracy Liu, Director, Product Management, Spear Bio

Before joining Spear Bio, Tracy Liu was Associate Director of Product Marketing at Quanterix, where she led strategic marketing initiatives for the Simoa® ultra-sensitive biomarker detection platform, including biomarker assay launches and cross-functional campaign alignment. She previously held senior roles in product management, marketing and technical service at Bio-Techne, Inscripta and Agilent Technologies, advancing innovative solutions in single-cell analysis, genome editing and next-generation sequencing.

Tracy holds a PhD in Cell and Molecular Biology from the University of Toledo and is passionate about translating complex life science technologies into impactful products that empower biomarker discovery and clinical research.

Message Presenter